- Home
- DPG vs FDMT Comparison
DPG vs FDMT Comparison
Compare DPG & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPG | FDMT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.2M | 449.6M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DPG | FDMT |
|---|---|---|
| Price | $14.68 | $11.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.71 |
| AVG Volume (30 Days) | 69.2K | ★ 875.6K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $12.13 | $3.68 |
| 52 Week High | $15.15 | $12.34 |
Technical Indicators
Market Signals| Indicator | DPG | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 62.90 |
| Support Level | $14.06 | $8.39 |
| Resistance Level | $14.71 | $11.85 |
| Average True Range (ATR) | 0.25 | 0.83 |
| MACD | 0.06 | 0.29 |
| Stochastic Oscillator | 99.98 | 74.54 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).